Want to see JP:6568 full AI Analyst Report?
KNC Laboratories Co.,Ltd. (6568) AI Stock Analysis
KNC Laboratories Co.,Ltd.
(TSE/TYO:6568)
KNC Laboratories earns a moderate score driven primarily by its appealing valuation and a highly stable balance sheet with minimal debt. However, these positive factors are offset by neutral technical momentum, narrowing profitability margins, and near-term cash burn from heavy capital investments.
KNC Laboratories Co.,Ltd. (6568) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 9.48B
- Dividend Yield
- 2.77%
- Average Volume (3M)
- 3,762
- Price to Earnings (P/E)
- 10.6
- Beta (1Y)
- 0.53
- Revenue Growth
- 12.39%
- EPS Growth
- 22.04%
- Country
- Japan
- Employees
- 340
- Sector
- General
- Sector Strength
- 55
- Industry
- Chemicals
KNC Laboratories Co.,Ltd. Business Overview & Revenue Model
Company Description
KNC Laboratories Co., Ltd. engages in research, development, and production solutions for organic chemicals. Its operations are carried out through the following business divisions: Functional Materials Business, Pharmaceutical Business, and Bio Busi...
How the Company Makes Money
null
KNC Laboratories Co.,Ltd. Financial Statement Overview
Summary
A strong, low-leverage balance sheet provides solid financial footing, but overall performance is weighed down by compressing profit margins and negative free cash flow due to elevated capital expenditures.
Income Statement
60NeutralBalance Sheet
80PositiveCash Flow
55Neutral| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.09B | 8.18B | 9.15B | 8.63B | 7.44B |
| Gross Profit | 2.39B | 2.27B | 3.24B | 3.26B | 2.06B |
| EBITDA | 2.29B | 1.83B | 3.02B | 3.10B | 1.86B |
| Net Income | 766.20M | 737.33M | 1.49B | 1.54B | 643.46M |
Balance Sheet | |||||
| Total Assets | 21.64B | 20.20B | 18.71B | 15.47B | 14.03B |
| Cash, Cash Equivalents and Short-Term Investments | 2.17B | 2.39B | 3.31B | 2.30B | 1.97B |
| Total Debt | 3.60B | 3.12B | 1.97B | 1.54B | 1.68B |
| Total Liabilities | 7.56B | 6.68B | 5.62B | 3.73B | 3.46B |
| Stockholders Equity | 14.08B | 13.52B | 13.09B | 11.75B | 10.58B |
Cash Flow | |||||
| Free Cash Flow | -363.52M | -1.82B | 850.16M | 863.73M | -248.27M |
| Operating Cash Flow | 2.26B | 1.49B | 3.20B | 1.99B | 585.11M |
| Investing Cash Flow | -2.70B | -3.32B | -2.37B | -1.15B | -613.51M |
| Financing Cash Flow | 222.35M | 909.60M | 178.87M | -523.39M | 39.02M |
KNC Laboratories Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6568, the sentiment is Negative. The current price of 1190.00 is below the 20-day moving average (MA) of 1263.10, below the 50-day MA of 1240.15, and below the 200-day MA of 1237.28, indicating a bearish trend. The MACD of 4.46 indicates Positive momentum. The RSI at 38.30 is Neutral, neither overbought nor oversold. The STOCH value of 34.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6568.
KNC Laboratories Co.,Ltd. Peers Comparison
Overall Rating
JP:436082Outperform- JP:656864Neutral
JP:436659Neutral
JP:496054Neutral
JP:453149Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4360 | 82Outperform | JPY 8.29B | 7.55 | ― | 1.56% | 19.58% | ― |
| JP:6568 | 64Neutral | JPY 9.43B | 10.63 | ― | 2.77% | 12.39% | 22.04% |
| JP:4366 | 59Neutral | JPY 14.12B | 10.44 | ― | 1.88% | 10.12% | 43.23% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4960 | 54Neutral | JPY 8.23B | 24.57 | ― | 1.00% | -5.34% | 113.57% |
| JP:4531 | 49Neutral | JPY 7.31B | 14.13 | ― | 3.01% | 3.90% | -31.32% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:6568 | KNC Laboratories Co.,Ltd. | 1190.00 | 119.65 | 11.18% | |
| JP:4360 | MANAC Chemical Partners Co.,Ltd | 959.00 | 393.90 | 69.71% | |
| JP:4366 | Daito Chemix Corporation | 407.00 | 150.33 | 58.57% | |
| JP:4531 | Yuki Gosei Kogyo Co., Ltd. | 332.00 | 57.94 | 21.14% | |
| JP:4960 | Chemipro Kasei Kaisya,Ltd. | 491.00 | 128.72 | 35.53% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026